Newroom
Promising new medicine SUL-238 (HCl salt of SUL-138) has a new publication: Safety study SUL-138 in rat and minipig
Sulfateq is happy to announce that a new scientific manuscript detailing the safety of SUL-138 is published in the leading journal Toxicology Reports. This manuscript details the safety, tolerability and toxicokinetic data of SUL-138, an obligatory...
Dagblad van het Noorden ‘Een nieuw molecuul uit Groningen als wapen tegen oude ziektes’
SUL-238: A Groundbreaking First-in-Class Medication Targeting Mitochondrial Dysfunction in Multiple Chronic Diseases
This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and...
Major breakthrough in potential new treatment for Sepsis with Sulfateq’s lead compound SUL-138
Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients....
Sulfateq is proud to announce the results of a new study which might provide a new way to treat Alzheimer’s disease.
Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of...
Sulfateq is in the finals of the LIFE Science Innovation Award!
We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we...